Obasa Gbenga Benjamin, Ijaiya Mukhtar, Okwor Ejike, Dare Babafemi, Emerenini Franklin, Oladigbolu Remi, Anyanwu Prince, Akinjeji Adewale, Brickson Kate, Zech Jennifer, Ogundare Yemisi, Atuma Emmanuel, Strachan Molly, Fayorsey Ruby, Curran Kelly
Jhpiego, Ankuru, Nigeria.
ICAP Global Health, Abuja, Nigeria.
PLOS Glob Public Health. 2024 Nov 22;4(11):e0002876. doi: 10.1371/journal.pgph.0002876. eCollection 2024.
The WHO recommends monitoring viral load (VL) to gauge ART efficacy among People Living with HIV (PLHIV). Low suppression rates persist in low- and middle-income countries due to poor adherence. Enhanced Adherence Counseling (EAC) aims to improve adherence and treatment outcomes. This study, part of the Reaching Impact Saturation and Epidemic Control (RISE) project in Nigeria, analyzes factors affecting viral re-suppression post-EAC. It aims to inform clinical decisions and improve PLHIV health outcomes in the country. This was a retrospective analysis of a de-identified client-level dataset of unsuppressed VL clients who were current on treatment at the end of June 2022 and subsequently enrolled in the EAC program. A log-binomial regression model was used to report crude and adjusted risk ratio with 95% Confidence Intervals (95% CI) and a p-value of 0.05 to determine the association between clinical characteristics and suppression of VL post-EAC in the RISE program (July 2021 to June 2022). A total of 1607 clients with initial high VL who completed EAC were included in this analysis out of which 1454 (91%) were virally suppressed. The median time to completion of EAC was 8 weeks and the median time for post EAC VL test was 8 weeks. Following EAC, PLHIV in the 10-19 years age band were 10% more likely to be re-suppressed (ARR: 1.10; 95% CI 1.01 to 1.19). In addition, there was a 50% reduced likelihood of viral re-suppression among PLHIV on second-line regimens compared to PLHIV on first-line regimens (ARR: 0.50; 95% CI 0.41 to 0.62). Findings show that Age and ART regimen were significant predictors of VLS. More targeted outreach of EAC amongst second-line regimens and ages 10 and above is necessary to ensure better VLS within these groups.
世界卫生组织建议监测病毒载量(VL),以评估艾滋病毒感染者(PLHIV)的抗逆转录病毒治疗(ART)效果。由于依从性差,低收入和中等收入国家的病毒抑制率一直较低。强化依从性咨询(EAC)旨在提高依从性和治疗效果。本研究是尼日利亚“达到影响饱和与疫情控制”(RISE)项目的一部分,分析了EAC后影响病毒重新抑制的因素。其目的是为该国的临床决策提供信息,并改善艾滋病毒感染者的健康状况。这是一项对匿名客户级数据集的回顾性分析,该数据集来自2022年6月底未实现病毒抑制但仍在接受治疗且随后参加了EAC项目的客户。使用对数二项回归模型报告粗风险比和调整后的风险比以及95%置信区间(95%CI)和p值为0.05,以确定RISE项目(2021年7月至2022年6月)中临床特征与EAC后病毒抑制之间的关联。本分析共纳入1607名初始病毒载量高且完成EAC的客户,其中1454名(91%)实现了病毒抑制。完成EAC的中位时间为8周,EAC后病毒载量检测的中位时间为8周。接受EAC后,10至19岁年龄组的艾滋病毒感染者重新被抑制的可能性高出10%(调整后风险比:1.10;95%CI为1.01至1.19)。此外,与接受一线治疗方案的艾滋病毒感染者相比,接受二线治疗方案的艾滋病毒感染者病毒重新抑制的可能性降低了50%(调整后风险比:0.50;95%CI为0.41至0.62)。研究结果表明,年龄和抗逆转录病毒治疗方案是病毒抑制的重要预测因素。有必要在二线治疗方案以及10岁及以上人群中更有针对性地开展EAC推广,以确保这些群体中实现更好的病毒抑制。